Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
57 results about "VASCULAR EMBOLISM" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Arterial embolism is a sudden interruption of blood flow to an organ or body part due to an embolus adhering to the wall of an artery blocking the flow of blood, the major type of embolus being a blood clot (thromboembolism).
Endovascular snare for capture and removal of arterial emboli
A snare for capture and removal of arterial emboli is disclosed. The snare is formed from a basket of interlaced filamentary members or a skeleton of interconnected flexible members. The basket has an opening at one end. A tongue extends from the basket adjacent to the opening, the tongue being offset from the basket centerline. A tether is attached to the tongue. The basket is collapsible into a collapsed configuration for delivery within an artery via a catheter. The basket is resiliently biased to expand into an open configuration upon release from the catheter. The tongue has a leading edge that engages the embolus and separates it from the artery when the snare is drawn toward it using the tether.
Owner:STOUT MEDICAL GROUP
Histotripsy for thrombolysis
Methods for performing non-invasive thrombolysis with ultrasound using, in some embodiments, one or more ultrasound transducers to focus or place a high intensity ultrasound beam onto a blood clot (thrombus) or other vascular inclusion or occlusion (e.g., clot in the dialysis graft, deep vein thrombosis, superficial vein thrombosis, arterial embolus, bypass graft thrombosis or embolization, pulmonary embolus) which would be ablated (eroded, mechanically fractionated, liquefied, or dissolved) by ultrasound energy. The process can employ one or more mechanisms, such as of cavitational, sonochemical, mechanical fractionation, or thermal processes depending on the acoustic parameters selected. This general process, including the examples of application set forth herein, is henceforth referred to as “Thrombolysis.”
Owner:RGT UNIV OF MICHIGAN
Blood vessel embolization method using balloon catheter and balloon catheter for blood vessel embolization method
A blood vessel embolization method includes inserting a balloon catheter into a blood vessel of a human or an animal having a lesion site and disposing a balloon of the balloon catheter at a portion located at a proximal side of the blood vessel and in a neighborhood of the lesion site thereof; shutting off a blood flow in the blood vessel by expanding the balloon; discharging a glucose solution from a distal end of the balloon catheter in a state in which the blood flow in the blood vessel is shut off; discharging a cyanoacrylate-based embolization substance-containing liquid from the distal end of the balloon catheter after the glucose solution injection step; hardening an embolization substance by maintaining a blood flow shut-off state of the blood vessel after the embolization substance injection step; and removing the balloon catheter from the blood vessel after the embolization substance-hardening step.
Owner:ST MARIANNA UNIV SCHOOL OF MEDICINE +1
Novel cerebral thrombus removal device and method for removing thrombus by using device
The invention relates to the technical field of medical apparatus and instruments, in particular to a novel cerebral thrombus removal device and a method for removing a thrombus by using the device. The cerebral thrombus removal device includes a stent and a transportation system connected with the near end of the stent, the stent is of a self-expansion pipe network structure formed through mutualconnection of multiple mesh units, the surface of the stent is curved in a wave shape, the stent is transported to the vascular embolism position of an intracranial great vessel through the transportation system, the stent of the pipe network structure is unfolded through self-expansion, and the thrombus is captured. The surface of the stent is arranged to be curved in a wave shape, so that the contact area of the surface of the stent and a vessel wall is small, the metal coverage is low, in the process of thrombus removal, damage to the intima of the vessel is less, friction between the thrombus and the vessel wall is reduced at the same time, and therefore the thrombus is easy to remove and maintained to be relatively integrated to prevent thrombus debris from entering the far end or anormal vessel; the thrombus can be removed fast, and the stability of thrombus removal is enhanced.
Owner:北京久事神康医疗科技有限公司
Vascular Embolus Of Paclitaxel-Sodium Alginate Microsphere And Its Preparation
Vascular embolus of paclitaxel-sodium alginate microsphere and its preparation. The preparation of it consists of the following steps: preparing the solution of paclitaxel, sodium alginate and dilvalent metal cations such as BaCl2 or CaCl2 etc. by order; mixing the paclitaxel solution and sodium alginate solution, and then mixing them with the curing solution of BaCl2 or CaCl2 and the like. Then the obtained is the sodium alginate microshere vascular embolus containing paclitaxel. The carrier materials of the vascular embolus according to the invention are natural extracts and have good biocompatibility and re biodegradable; the side effect of the pharmaceutic loaded by them is minimal, and it is therefore suitable for the vascular embolism and chemotherapy against the tumor.
Owner:BEIJING HONGYIYAO SCI & TECH DEV
Mechanical embolism conveying instrument and mechanical embolism conveying method
The invention relates to a mechanical embolism conveying instrument and a mechanical embolism conveying method. A vascular embolism spring ring system comprises an implantation object constituted by an embolism spring ring; a releasing lining assembly connected with the embolism spring ring; and a releasing conveying conductor (DDW) assembly. The releasing conveying conductor (DDW) assembly comprises an external pushing assembly and an internal traction conductor. The internal traction conductor comprises a far-end area having an increased diameter. The external pushing assembly also comprises a far-end spring tube provided with a flexible far-end area and a near-end micro-internal diameter tube. The object of the invention to release the spring ring by using the instrument releasing system is achieved, and complete releasing is guaranteed. Both of the reliability and the firmness of the mechanical instrument in an operation process are considered.
Owner:珠海葛瑞医疗器械有限公司
Degradable chitosan-based composite hemostatic film
ActiveCN112717194AMeet the mechanical performance requirementsStrong humidityAbsorbent padsCoatingsFiberPolyethylene glycol
The invention discloses a degradable chitosan-based composite hemostatic film which comprises a base material layer and a functional layer, and is characterized in that the base material layer is degradable fiber cloth; the functional layer is composite hydrogel prepared from modified chitosan, polyethylene glycol 2000, gelatin, xanthan gum, Ag / Fe2O3 magnetic nanoparticles, forged ophicalcitum and oleamide, and the functional layer is combined with the base material layer through polydopamine. The degradable chitosan-based composite hemostatic film provided by the invention has the advantages of softness, air permeability, high safety, good mechanical properties, strong water absorption and retention capacity, capability of being tightly attached to a wound, easiness in stripping, hemostasis, good anti-infection effect and no side effect of vascular embolism.
Owner:HENAN YADU IND
Microvascular anastomat
Disclosed is a microvascular anastomat. The microvascular anastomat is characterized in that the microvascular anastomat comprises two cannulas same in diameter, a sliding rod, an anastomosis nail anda nail base; each cannula is a tubular member formed by splicing two arc tube sheets in a hinged mode, a flanging arranged at the periphery of a tube opening in one end of each cannula, and a plurality of negative pressure holes are formed in the flangings around the tube opening; the sliding rod is a rod-shaped member, and the outer walls of the two cannulas are both connected with the sliding rod in a symmetrical and sliding mode, wherein the flangings of the two cannulas are opposite to each other; the nail base is a semi-annular member and is fixedly arranged on the sliding rod and located between the two cannulas; the main body of the anastomosis nail is an annular member, the annular member is fixedly provided with a plurality of pins parallel to the central axes of the cannulas, the middle of each pin is fixed to the annular member, and the whole anastomosis nail on the annular member is fixed on the nail base. The microvascular anastomat is simple in structure, the inner membrane eversion of microvessel is maintained after anastomosis, the contact area between the anastomosis nail and the micorvessel after an operation is small, and the risk of postoperative vascular embolism is greatly reduced.
Owner:王培吉
Notoginseng triol-saponin composition and its prepn and use
ActiveCN1771978AEasy to dredgeStrong targetingOrganic active ingredientsBlood disorderDiseaseMedicine
The present invention belongs to the field of Chinese medicine, and is especially the purified product of notoginseng as one kind of Chinese medicinal materials and its preparation process and pharmaceutical use. The notoginseng triol-saponin composition obtained through purifying notoginseng consists of ginsenoside Rg1, ginsenoside Re and saponin R1 as main components, and contains ginsenoside Rg1 30-70 wt%, ginsenoside Re 4-15 wt% and saponin R1 7-25 wt%, with the total content of ginsenoside Rg1, ginsenoside Re and saponin R1 being up to 98 wt%. The notoginseng triol-saponin composition has obvious treating effect on vascular embolism diseases, and is used in preparing medicine for treating vascular embolism diseases.
Owner:CHENGDU HUASUN GRP INC LTD
Thrombin-loaded microsphere-expanded sponge composite hemostatic material and preparation method and application thereof
ActiveCN111053944APrevent leakageAvoid leakage intoSurgical adhesivesPharmaceutical delivery mechanismMicrosphereThrombin activity
A thrombin-loaded microsphere-expanded sponge composite hemostatic material and a preparation method and application thereof are disclosed. According to the prepared thrombin-loaded microsphere-expanded sponge composite hemostatic material, thrombin with hemostatic activity is loaded in microspheres, and the thrombin-loaded microspheres are loaded on the sponge with good swelling rate and swellingproperty. Through synergistic exertion of advantages of three ingredients, the expanded sponge with a good swelling rate can rapidly absorb moisture in blood so as to concentrate blood coagulation factors and accelerate hemostasis; the expanded sponge can generate physical compression on damaged tissues and promote hemostasis; thrombin is loaded through the microspheres, so that thrombin can be prevented from leaking and entering blood vessels to cause vascular embolism, and thrombin activity can be retained; and thrombin loaded with hemostatic active ingredients can activate a blood coagulation path to accelerate hemostasis. In addition, the microsphere-sponge composite hemostatic material has good biocompatibility, raw material sources are abundant, and the cost is controllable. Therefore, the microsphere-sponge composite hemostatic material has good clinical application prospects.
Owner:安徽中科迈德医疗科技有限公司
Device and system used for forming vascular embolism and application of device and system
The invention provides a device and system used for forming vascular embolism and application of the device and the system. The device is a 'sandwich' structure penetrated by a guidance guide wire and comprises the guidance guide wire, a first half balloon body, a second half balloon body, a sponge body and a pushing rod. The head end and the tail end are defined for the guidance guide wire; a first half balloon inner cavity is formed in the center of the first half balloon body, and the first half balloon body is arranged on the guidance guide wire in a sleeved mode through the first half balloon inner cavity; a second half balloon inner cavity is formed in the center of the second half balloon body, and the second half balloon body is arranged on the guidance guide wire in a sleeved mode through the second half balloon inner cavity; the sponge body is arranged between the first half balloon body and the second half balloon body, and the guidance guide wire penetrates through the sponge body; the pushing rod and the second half balloon body are connected into a whole. The device can effectively embolize the blood vessel and accurately control the embolism level.
Owner:GENERAL HOSPITAL OF PLA
177Lu-loaded degradable polymer material microsphere as well as preparation method and application thereof
ActiveCN114504661ALight weightImprove stabilityPowder deliveryRadioactive preparation carriersEngineeringVASCULAR EMBOLISM
The invention discloses a 177Lu-loaded degradable polymer material microsphere as well as a preparation method and application thereof. The microsphere sequentially comprises a chitosan layer, a 177Lu labeled polydopamine layer and a polydopamine blocking layer from inside to outside. The preparation method comprises the following steps: S1, preparing a chitosan microsphere suspension by adopting an emulsification cross-linking method; and S2, marking polydopamine with 177Lu, wrapping the outer side of the chitosan microsphere with the 177Lu marked polydopamine, and meanwhile, forming a polydopamine blocking layer on the outer side of the 77Lu marked polydopamine, so that the degradable high polymer material microsphere is obtained. The microsphere disclosed by the invention has good biocompatibility and small specific gravity, releases gamma rays capable of being used for nuclide imaging, and solves the problems that the existing 90Y microsphere high-specific-gravity material causes non-uniform distribution in a drug body, the material is difficult to degrade, so that repeated treatment cannot be performed, and real-time image monitoring of drug distribution in the body of a postoperative patient is difficult. The microsphere disclosed by the invention is stable in load and suitable for non-permanent radioactive vascular embolism treatment.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Antibacterial chitosan-based hemostatic patch
ActiveCN112791223AAdhesiveStrong water absorption and retention capacitySurgical adhesivesFibre typesPolyethylene terephthalate glycolPolyethylene Terephthalates
The invention discloses an antibacterial chitosan-based hemostatic patch, which comprises a back lining layer, a hemostatic layer and a protective layer which are sequentially arranged from bottom to top; the back lining layer is a base material prepared from polypropylene or polyethylene terephthalate, and an adhesive is coated on the back lining layer; the hemostatic layer comprises a non-woven fabric on the lower side and a composite hemostatic material on the upper side, and the composite hemostatic material is composite hydrogel prepared from modified chitosan, polyethylene glycol 2000, gelatin, xanthan gum, a tea polysaccharide-nano-selenium compound, dopamine modified nano-silica and oleamide; and the protective layer is a PET (Polyethylene Terephthalate) film. The antibacterial chitosan-based hemostatic patch provided by the invention is convenient to store, carry and use, does not stimulate wounds, has good antibacterial and anti-infection effects, can realize rapid blood coagulation through adhesion sealing and activation of a blood coagulation system, and can avoid the occurrence of side effects of vascular embolism.
Owner:HENAN YADU IND
Anti-tumor vascular embolism agent containing asparagus deproteinized polysaccharide and preparation method thereof
InactiveCN102579476AEnhance immune functionReduce infectionOrganic active ingredientsPharmaceutical delivery mechanismMedicinal herbsVASCULAR EMBOLISM
The invention belongs to the field of traditional Chinese medicines, and relates to an anti-tumor vascular embolism agent containing asparagus deproteinized polysaccharide and a preparation method thereof. According to the invention, the asparagus deproteinized polysaccharide is obtained from asparagus, i.e., a Chinese medicinal crop, through preparation processes such as extraction, deproteinization, purification and drying; and the asparagus deproteinized polysaccharide is added into iodine-containing solution to be prepared into a refined asparagus colloidal preparation of which every 100 ml contains 2.0-50.0 g of asparagus deproteinized polysaccharide. Experiments prove that the embolism agent has low toxicity, high compatibility with a water-soluble anti-tumor medicament and a medicament slow release effect; after the embolism agent is injected into hepatic artery, obstruction of local blood vessel can be caused to result in necrosis of tumor tissues; and the embolism agent also has a direct tumor suppression pharmaceutical effect and functions of straightening the body resistance and improving immunity and is an ending anti-tumor embolism agent with a good effect. According to the preparation method provided by the invention, the active ingredients in the medicinal crop can be efficiently reserved, the preparation of a Chinese medicinal preparation is simplified, the environment is protected, and the operation of batch production is facilitated.
Owner:SHANGHAI HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Injection type facial filler composition gel for cosmetic and plastic surgery and preparation method of injection type facial filler composition gel
InactiveCN113941027AEasy to useImprove bindingPharmaceutical delivery mechanismProsthesisCollagenanVASCULAR EMBOLISM
The invention discloses an injection type facial filler composition gel for cosmetic and plastic surgery, and belongs to the technical field of medical treatment. The injection type facial filler composition gel is prepared from the following components in parts by weight: 10-20 parts of sodium hyaluronate, 90-100 parts of an aqueous solution for injection, 2-5 parts of collagen powder, 5-8 parts of modified particles, 0.1-0.2 part of an extraction agent, and 0.4-0.7 part of multivitamins. The injection type facial filler composition gel is safe to use, the problems of redness, swelling, vascular embolism and the like are solved, and the treated skin is attractive and natural.
Owner:珠海美如初医疗美容有限公司
Construction of Arterial Occlusive Disease Animal Model
InactiveUS20080295189A1Stable pathologic conditionImprove certaintyCompounds screening/testingTomographyArterial Occlusive DiseasesArterial site
The present invention relates to a method for generating a non-human model animal of an arterial occlusive disease, wherein the method is characterized in that an artery is occluded at a specific site by ligating it or with an autologous blood clot. In particular, the present invention relates to a method and a kit for generating a cardiac infarction model, as well as a cardiac infarction animal model obtained by employing the method or kit, characterized in that in a non-human experimental animal, a blood vessel is ligated downstream of an arterial site of the heart to be occluded, followed by occluding the artery at said site. In addition, the present invention also relates to a method and a system for generating a non-human animal model of arterial embolus, as well as an arterial embolus animal model obtained by employing the method or system, characterized by adding an coagulating agent to autologous blood to form an autologous blood clot and subsequently employing an angiographic apparatus in delivering the autologous blood clot into an artery.
Owner:HEALTH SCI TECH TRANSFER CENT JAPAN HEALTH SCI FOUND
Amino acid derivative, preparation method and application thereof
The invention discloses an amino acid derivative capable of being used for inhibiting blood coagulation factor XIa and application of the amino acid derivative. The invention provides a compound as shown in a formula I or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorphic substance, a solvate, N-oxide, metabolite or a prodrug thereof. According to the invention, a plurality of in-vitro biological test results show that an obvious inhibitory activity effect can be generated on a blood coagulation factor (Factor XIa) at an extremely low concentration, some of the preferred compounds can significantly prolong the human whole blood coagulation time under the condition of low concentration, whether the coagulation time is 1.5 times or 2.0 times, and the compound achieves a practical standardand has an optimistic patent medicine prospect; and the compound can be used as an inhibitor of a blood coagulation factor XIa, and a pharmaceutical composition containing the compound, a preparation method of the compound and application of the compound in preparation of drugs for preventing or treating thrombus and vascular embolism related diseases are provided.
Owner:西安禾渼生物医药有限公司
Vascular embolism spring ring system
The invention provides a vascular embolism spring ring system. The system comprises a pushing rod with an inner cavity, a releasing wire, a releasing ball and an embolism spring ring connected with the releasing ball; the releasing wire and the releasing ball are arranged in the inner cavity; and a limiting notch is formed in the side wall, close to the far end, of the inner cavity of the pushing rod. The releasing ball is matched with the limiting notch under the action of the releasing wire so as to be limited in the inner cavity of the pushing rod; the releasing ball is connected with a connecting wire; a near-end connecting piece is arranged at the near end of the pushing rod; and the releasing ball is matched with the limiting notch under the action of the releasing wire to be limited in the inner cavity of the pushing rod, so that the embolism spring ring is limited, a limiting step or an end cover for limiting the releasing ball does not need to be arranged at the far-end port of the pushing rod, the problem that the releasing ball is blocked by the limiting step or the end cover and cannot be released when being released from the far-end port is solved, and the releasing ball can be conveniently, rapidly and accurately released from the pushing rod when the releasing wire is pulled out.
Owner:ZHUHAI TON-BRIDGE MEDICAL TECH CO LTD
A microvascular stapler
InactiveCN107536631BEasy to disengageExact fitSurgical staplesVascular anastomosisStapled anastomosis
Owner:王培吉
Hemangioma plugging device, hemangioma plugging treatment device and hemangioma plugging system
The invention relates to a hemangioma plugging device, a hemangioma plugging treatment device and a hemangioma plugging system.The hemangioma plugging device comprises a net-shaped expansion structure and a guiding structure, and the net-shaped expansion structure has an unfolded state in which the net-shaped expansion structure is wound into a spiral shape from the far end to the near end and a compressed state in which the net-shaped expansion structure is delivered to hemangioma from the inside of a blood vessel; at least one part of the guide structure is arranged in an inner cavity of the net-shaped expansion structure, and when the net-shaped expansion structure is in a spiral shape, at least one part of the guide structure is unfolded in the inner cavity of the net-shaped expansion structure to be in a spiral shape. According to the invention, stable and compliant filling is realized, and the method also has the advantages of preventing hemangioma rupture, preventing vascular embolism, improving the coverage rate of a tumor neck opening, promoting the formation of thrombus in a tumor, accelerating hemangioma embolism and the like.
Owner:MICROPORT NEUROTECH SHANGHAI
Hydrogel vascular embolism material and shape memory embolism treatment method
ActiveCN110559470ASimple preparation processReduce manufacturing costSurgical adhesivesHydrophilic monomerCross-link
The invention discloses a hydrogel vascular embolism material and a shape memory embolism treatment method. The hydrogel vascular embolization material is obtained by free radical copolymerization ofa hydrophobic monomer containing a benzene ring, a hydrophilic monomer capable of forming an intermolecular hydrogen bond and a cross-linking agent, the hydrogel vascular embolization material is formed by crosslinking physical crosslinking points formed by hydrophobic association and hydrogen bond interaction and covalent crosslinking points generated by chemical crosslinking. The vascular embolism material can achieve the purpose of vascular embolism, has excellent mechanical properties, and has the characteristics of relatively high breaking strain and breaking stress, excellent fatigue resistance, excellent resilience and the like.
Owner:ZHEJIANG UNIV
Application of recombinant human hyaluronidase preparation
PendingCN114681594ASolve injection side effectsAddressing overdosage but ineffectivenessPeptide/protein ingredientsAntipyreticActive agentSurface-active agents
The invention discloses an application of a recombinant human hyaluronidase preparation. The recombinant human hyaluronidase preparation is prepared from recombinant human hyaluronidase, a buffering agent, a stabilizing agent and a nonionic surfactant, wherein the enzyme activity of the recombinant human hyaluronidase is 45 to 450,000 units / ml; the concentration of the buffering agent is 5-50 mM; the concentration of the stabilizer is 1-500mM, and the stabilizer is selected from one or more of trehalose, cane sugar, mannitol, sodium chloride and methionine; the concentration of the nonionic surfactant is 0.01%-0.1% (w / v); the pH value of the recombinant human hyaluronidase preparation is 5.0 to 8.0. The problems that when an existing clinically-used hyaluronidase extraction product is used for treating, correcting or preventing side reactions such as vascular embolism, excessive filling or uneven filling caused by hyaluronic acid filling, the intravenous administration dosage is too large, the effect is poor, and subcutaneous local treatment is poor in safety and curative effect can be solved.
Owner:SHANGHAI BAO PHARM CO LTD
Preparation and application of chitosan and propylene glycol alginate blended microcapsules
ActiveCN109126648AGood biocompatibilityPromote degradationCosmetic preparationsSurgical adhesivesDrug carrierCatheter
The invention provides preparation and application of chitosan and propylene glycol alginate blended microcapsules, and relates to the field of microcapsule preparation and application. Chitosan is dissolved by an acetum solution with the mass percent concentration of 0.5-5%, propylene glycol alginate is dissolved by water, then the two solutions are blended, under a high-voltage static field, theblended solution is extruded into a 2-8% NaOH aqueous solution to form wet blended microcapsules, and after washing and drying, the dried blended microcapsules are obtained. The prepared chitosan andpropylene glycol alginate blended microcapsules can be taken as embolism substances for vascular embolism, the embolism substances are injected or conveyed into the target blood vessel through a catheter, so that the blood vessel at the target position is blocked, good expansibility can avoid that the microcapsules move in the blood vessel, the structures of the microcapsules are stable, and embolism can be more stable; the microcapsules can be applied to slow-release medicine and taken as a carrier of the slow-release medicine, the blended microcapsules are combined with the medicine to achieve the slow releasing effect of the medicine, and good slow releasing performance is achieved.
Owner:QINGDAO MINGYUE BIOMEDICAL MATERIALS
Hemangioma plugging device, hemangioma plugging treatment device and hemangioma plugging system
The invention relates to a hemangioma plugging device, a hemangioma plugging treatment device and a hemangioma plugging system. The hemangioma plugging device comprises a net-shaped expansion structure and a positioning guide structure, wherein the net-shaped expansion structure has a plane vortex-shaped expansion state; the positioning guide structure has a three-dimensional spiral expansion state, after the hemangioma plugging device is expanded, one part of the positioning guide structure is spirally arranged in a central cavity of the plane vortex, and the other part of the positioning guide structure is located outside the plane vortex, so that positioning and guiding are carried out through the positioning guide structure, the whole device is stable, the device can be stably positioned in a tumor for a long time and is not easy to move, and a tumor cavity can be filled and stably supported through the net-shaped expansion structure. While realizing stable filling, the hemangioma plugging device also has the advantages of preventing the rupture of hemangioma, preventing vascular embolism, improving the coverage rate of the neck of the tumor, promoting the formation of thrombus in the tumor, accelerating the embolism of the hemangioma and the like.
Owner:MICROPORT NEUROTECH SHANGHAI
TNK-tPA fusion protein with enhanced transepithelial cell transport capacity, and application thereof
ActiveCN112111475AImprove absorption efficiencyImprove transportation capacityPeptide/protein ingredientsAntibody mimetics/scaffoldsAntibody fragmentsVASCULAR EMBOLISM
The invention discloses TNK-tPA fusion protein with an enhanced transepithelial cell transport capacity, namely TPAFcm fusion protein, which is formed by carrying out genetic engineering recombinationon TNK-tPA and a human antibody IgG2 Fc fragment mutant; compared with non-mutant TNK-tPAFc fusion protein, glycosyl modification of an Fc fragment is removed from the mutant TPAFcm, so that the transepithelial cell transport capacity of the TPAFcm is improved by more than three times; besides the general advantages of the antibody Fc fusion protein, the mutant fusion protein also has the advantage of high epithelial cell absorption efficiency and can be used for treating pulmonary embolism and preventing and treating other vascular embolism diseases; and a theoretical basis and a research basis are provided for developing a new dosage form of tenecteplase and widening the application range and the field of the tenecteplase.
Owner:JIANGSU FENGHUA BIOPHARMACEUTICAL CO LTD
Hemangioma plugging device, hemangioma plugging treatment device and hemangioma plugging system
The invention relates to a hemangioma plugging device, a hemangioma plugging treatment device and a hemangioma plugging system. The hemangioma plugging system comprises the hemangioma plugging device and a catheter. The hemangioma plugging device at least comprises a net-shaped expansion structure, and the net-shaped expansion structure has a planar spiral unfolded state and a compressed state for being delivered to hemangioma from the inside of a blood vessel. The net-shaped expansion structure is compressed in the catheter and can restore to a spiral unfolding state after being separated from the catheter; the hemangioma plugging treatment device comprises a hemangioma plugging device and a pushing rod, and the pushing rod is connected to the near end of the net-shaped expansion structure. According to the invention, stable and compliant filling is realized, and the method also has the advantages of preventing hemangioma rupture, preventing vascular embolism, improving the coverage rate of a tumor neck opening, promoting the formation of thrombus in a tumor, accelerating the embolism of the hemangioma and the like.
Owner:MICROPORT NEUROTECH SHANGHAI
Medicament for preventing or treating cardiovascular and cerebrovascular diseases
InactiveCN101919943AImprove immunityPromote circulationMetabolism disorderBlood disorderDiseaseSciatica
The invention discloses a medicament for preventing or treating cardiovascular and cerebrovascular diseases. The medicament comprises the following natural bulk pharmaceutical chemicals in parts by weight: 3-5 parts of gambir plant, 3-5 parts of red paeony root, 3-5 parts of oriental waterplantain rhizome, 5-8 parts of Spanishneedles herb, 3-5 parts of rehmannia root, 2-3 parts of photinia stem, 15-30 parts of chrysanthemum, 5-10 parts of barbary wolfberry fruit, 10-15 parts of green forsythia and 10-20 parts of shanzhi. The medicament has functions of inhibiting thrombosis, obviously increasing cerebral blood flow, dissolving thrombus, inhibiting platelet aggregation, reducing miocardial infarction area, reducing the total peripheral resistance of blood vessel and increasing cardiac coronary artery flow, can prevent or treat the diseases such as chest distress, angina, insomnia, headache, hemiplegia caused by cardio-cerebral vascular embolism, limbs stalemate, dribbling, local numbness, skin blood capillary burst and sciatica, and has specific curative effect on the cardiovascular and cerebrovascular diseases such as apoplexy, coronary heart disease, cerebral hemorrhage, cerebral thrombosis and other symptoms; and moreover, the medicament is a pure traditional Chinese medicine preparation, which has the advantages of reasonable formula, low cost, simple processing and obvious clinical effects and is highly praised by the patients and family members of the patients.
Owner:袁丽霞
Injectable hydrogels for vascular embolism
PendingCN114369354ASurgical adhesivesPharmaceutical delivery mechanismPolyethylene glycolVASCULAR EMBOLISM
The invention discloses injectable hydrogel for vascular embolism, which is formed by in-situ crosslinking of aldehyde-terminated star-shaped multi-arm polyethylene glycol, polyethyleneimine and polylysine, the molar ratio of aldehyde to amino in polyethyleneimine is 1: (0.6-5), and the molar ratio of aldehyde to amino in polylysine is 1: (0-5). The in-vitro gelling time of the hydrogel is equal to or less than 8 seconds, namely 8 seconds, and the hydrogel can quickly embolize blood vessels to cause necrosis of target organs or tissues.
Owner:SHANGHAI RUINING BIOTECH CO LTD
A kind of emulsified lipiodol vascular embolism material and its preparation method and application
ActiveCN107261197BLow viscositySmall doseSurgical adhesivesPharmaceutical delivery mechanismBlood flowActive agent
The invention relates to an iodinated lipid emulsion vascular thrombosis material, a preparation method and an application thereof, and belongs to the technical field of vascular thrombosis materials used in medical appliance intervention. The iodinated lipid emulsion vascular thrombosis material includes, by mass, 20-80% of iodinated lipid emulsion, 15-75% of temperature sensitive nano-hydrogel and 0.04-3.0% of a gelator; on the basis of the mass of the iodinated lipid emulsion, the iodinated lipid emulsion includes, by mass, 50-90% of lipiodol, 0.1-0.6% of a co-surfactant and the balanced water. The vascular thrombosis material is low in viscosity and is excellent in capability of resisting blood scouring, can form firm and durable thrombosis, can be image-developed for long period, brings convenience to reexamination and diagnosis of patients at any time, has better curative effects and is safe and controllable.
Owner:广东广纳安疗科技有限公司
An injectable facial filler composition for cosmetic plastic surgery and its preparation method
ActiveCN111249189BFully biodegradable withWide variety of sourcesCosmetic preparationsToilet preparationsCelluloseSkin repair
An injection-type facial filler composition for cosmetic plastic surgery and a preparation method thereof, which relates to a facial filler composition for cosmetic plastic surgery and a preparation method thereof. The purpose of the present invention is to solve the problems that the existing cross-linked hyaluronic acid has poor cross-linking effect, causes redness and swelling to users and leaves potential safety hazards, has no skin repairing effect and may cause blood vessel embolism. An injectable facial filler composition for plastic surgery includes cross-linked hyaluronic acid composite gel, hydroxyapatite particles, collagen powder, cellulose ethers, epimedium extract, white peony extract and injection Use an aqueous solution. Methods: 1. weighing; 2. mixing and sterilizing. The injection-type facial filler composition for cosmetic plastic surgery prepared by the present invention is used for injection into the dermis of the part of the face to be filled. The present invention can obtain an injectable facial filler composition for cosmetic plastic surgery.
Owner:陈勇
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com